Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 29, 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) on October 26, 2012, at a price of $45.35 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: October 26, 2012 (Notification date: October 29, 2012).
- Instrument: GSK American Depositary Shares (ADSs).
- Price: $45.35 per ADS.
- Beneficiary: Dr. K. Slaoui (Connected Person of Director Dr. M. M. Slaoui).
- Quantity: 4 ADSs allocated to the connected person.
- Director Activity: Dr. M. M. Slaoui had no direct allocation (-) in this specific transaction.